DURECT to Release Q3 2024 Financial Results and Business Update

DURECT Corporation, based in Cupertino, California, and listed on Nasdaq under the ticker DRRX, is a biopharmaceutical company focused on developing epigenetic therapies. These innovative treatments target abnormal DNA methylation and are designed to address severe and life-threatening conditions, such as acute organ injury.

On November 6, 2024, DURECT Corporation announced its upcoming financial results release for the third quarter of 2024. The results will be disclosed on Wednesday, November 13, 2024. Following the announcement, the company's management team will host a conference call and webcast for investors. This event is scheduled to start at 4:30 PM Eastern Time, or 1:30 PM Pacific Time. Participants can either dial in using provided guest numbers or utilize the Call me™ link for instant access, which will become active 15 minutes before the scheduled start.

DURECT is at the forefront of developing epigenetic treatments, with a particular focus on a drug candidate called Larsucosterol. This lead candidate targets DNA methyltransferases, enzymes that are often elevated in patients suffering from acute hepatic conditions, resulting in hypermethylation. Larsucosterol is currently undergoing clinical trials for the treatment of acute hepatic injury (AH). Notably, the U.S. Food and Drug Administration (FDA) has recognized Larsucosterol by granting it Fast Track and Breakthrough Therapy designations, underscoring its potential significance. Additionally, DURECT is exploring the use of Larsucosterol for treating MASH.

Apart from its work on Larsucosterol, DURECT has developed POSIMIR® (bupivacaine solution) for infiltration use. POSIMIR® is a non-opioid analgesic that employs the innovative SABER® platform technology. This product has received FDA approval and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution within the United States.

DURECT Corporation's commitment to pioneering new treatments through epigenetic therapy holds promise for patients with severe and life-threatening conditions. With their ongoing clinical developments and strategic partnerships, DURECT is poised to make significant contributions to the medical field, particularly in the area of acute organ injuries and pain management.